Hillary Stemple

4 weeks ago | jdsupra.com | Aida Al-Akhdar |Hillary Stemple |Stephanie Trunk

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of the Inspector General (OIG), manufacturers have contested the OIG’s long-standing interpretation of the Anti-Kickback Statute (AKS).

1 month ago | afslaw.com | Stephanie Trunk |Hillary Stemple |Aida Al-Akhdar

On In a ruling issued on March 31, a federal judge upheld the OIG’s interpretation of the AKS, which formed the basis for the agency issuing an unfavorable advisory opinion to Vertex Pharmaceuticals Incorporated regarding the company’s proposed fertility assistance program. The court’s ruling is the latest blow to the pharmaceutical industry’s efforts to narrow the scope of the AKS.

Dec 16, 2024 | jdsupra.com | Hillary Stemple

Headlines that Matter for Companies and Executives in Regulated IndustriesFlorida Telemarketer Sentenced to 15 Years in Prison for $67 Million Medicare Fraud SchemeOn December 6, Jose Goyos was sentenced to 15 years in prison for his role in managing a deceptive telemarketing scheme to defraud Medicare of over $67 million for medically unnecessary genetic testing. He had been convicted of conspiracy to commit wire fraud and conspiracy to commit money laundering.

Jul 30, 2024 | jdsupra.com | Pascal Naples |D. Jacques Smith |Hillary Stemple

Previously, we discussed how the US Supreme Court’s opinion in Loper Bright Enterprises v. Raimondo and Relentless, Inc. v. Department of Commerce could create opportunities for private litigants to challenge health care-related agency actions, particularly with respect to the Stark Law (42 U.S.C. § 1395nn(a)(1)). Read our prior discussion here.

Jul 29, 2024 | afslaw.com | D. Jacques Smith |Hillary Stemple |Pascal Naples

On Read our prior discussion here. To recap, the Court’s opinion in Loper Bright requires courts to exercise “independent judgment” when reviewing an agency’s interpretation of a statute rather than deferring to that agency’s interpretation under Chevron.